Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus.
The use of adenovirus vector-based vaccines is a promising approach for generating antigen-specific immune responses. Improving vaccine potency is necessary in other approaches to address their inadequate protection for the majority of infectious diseases. This study is the first to reconstruct a recombinant replication-defective human adenovirus co-expressing E2 and invasin C-terminal (InvC) glycoproteins (rAd-E2-InvC). rAd-E2-InvC with 2 x 10(6) TCID50 was intramuscularly administered two times to CSFV-free pigs at 14 day intervals. No adverse clinical reactions were observed in any of the pigs after the vaccination. The CSFV E2-specific antibody titer was significantly higher in the rAd-E2-InvC group than that in the rAdV-E2 group as measured by NPLA and blocking ELISA. Pigs immunized with rAd-E2-InvC were completely protected against lethal challenge. Neither CSFV RNA nor pathological changes were detected in the tissues after CSFV challenge. These results demonstrate that rAd-E2-InvC could be an alternative to the existing CSF vaccine. Moreover, InvC that acts as an adjuvant could enhance the immunogenicity of rAdV-E2 and induce high CSFV E2-specific antibody titer and protection level.
College of Veterinary Medicine, Northwest A and F University, Yangling 712100, Shaanxi, China.
Helin
H
Li
Pengbo
P
Ning
Zhi
Z
Lin
Wulong
W
Liang
Kai
K
Kang
Lei
L
He
Yanming
Y
Zhang
D017502:Adenovirus E2 Proteins / Q000276:immunology*; D000260:Adenoviruses, Human / Q000276:immunology; D018829:Adhesins, Bacterial / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D002460:Cell Line; D006691:Classical Swine Fever / Q000276:immunology*; D006692:Classical Swine Fever Virus / Q000276:immunology; D006023:Glycoproteins / Q000096:biosynthesis / Q000276:immunology; D057809:HEK293 Cells; D006801:Humans; D011897:Random Allocation; D013552:Swine; D014611:Vaccination; D064166:Vaccine Potency; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014779:Virus Replication / Q000235:genetics; D015008:Yersinia enterocolitica / Q000276:immunology; D015011:Yersinia pseudotuberculosis / Q000276:immunology
D017502:Adenovirus E2 Proteins; D018829:Adhesins, Bacterial; D000914:Antibodies, Viral; D006023:Glycoproteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C053476:invasin, Yersinia